Navigation Links
ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs
Date:3/25/2009

FREDERICK, Md., March 25 /PRNewswire/ -- ImQuest Life Sciences presented their latest biological results supporting the continued development of their small molecule pyrimidinedione inhibitors of HIV-1 at the Prevention of meeting being held in Keystone, Colorado. The presentations highlighted new data supporting the selection of lead second generation therapeutic agents with an increased barrier to the selection of drug resistant virus strains in treated patients, as well as preclinical studies supporting the development of the pyrimidinedione IQP-0528 as a topical microbicide candidate for human clinical trials. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription, a highly positive safety profile, and enhanced sensitivity against multi-drug resistant viruses isolated from patients. ImQuest recently submitted an Investigational New Drug Application to the FDA to initiate Phase 1 human clinical trials with the pyrimidinedione IQP-0410.

Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer) presented the results of studies which demonstrate the ability of various analogs of IQP-0410 to more effectively suppress the replication of viruses which are resistant to the action of other NNRTIs used in the clinic. ImQuest, in collaboration with their drug development partner Samjin Pharmaceutical Co. Ltd of Seoul, Korea, have recently engaged in an effort to develop more active pyrimidinediones possessing this higher genetic barrier to resistance. Karen M. Watson, M.S. (Director, Topical Microbicide Research & Development) reported on results of preclinical efficacy evaluations of a series of pyrimidinediones, resulting in the selection of IQP-0528 as ImQuest's lead compound to prevent the sexual transmission of HIV worldwide. The studies included ImQuest co-authors Tracy Hartman, M.S., Lu Yang, M.D. and Christa E. Buckheit, as well as collaborators Patrick Kiser, Ph.D., Alamelu Mahalingham and Todd Johnson of The University of Utah.

"These results highlight the significant potential of the pyrimidinediones as highly potent therapeutic and preventative agents and provide additional rationale for their expedited development," said Dr. Buckheit. "We appreciate the continued support of these development programs by the National Institutes of Health (NIAID) and the International Partnership for Microbicides, as well as our close partnership with the chemistry team at Samjin."

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
3. Accuray to Webcast Senior Management Presentations at Analyst Day Event
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
5. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
6. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts
9. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
10. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
11. Trubion Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the ... healthy lifestyles and highlighting the importance of proactive eye and ear health. The ... the latest innovations in hearing aid technology. , In this issue, the ...
(Date:8/18/2017)... WV (PRWEB) , ... August 18, 2017 , ... ... financial consulting services and asset protection assistance to communities in North-Central West Virginia, ... provide critical services to at-risk boys in the area. , The Chestnut Mountain ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates ... residential and commercial clients in the greater Houston region, is helping locally recognized ... the fight against cancer. , Founded by Tony and Amber Bender after losing ...
(Date:8/18/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has released a new publication this ... of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared to what ... historical woman. , “The world bows, kisses the feet of, cries out to and ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... 15, 2017  AOTI Inc. announced today that its fully owned ... recently opened a New York City Office in Yonkers, ... unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This new ... for Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable ... Advanced ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: